Investors have ignored NaPro BioTherapeutics Inc. since December 1997, when then-partner Ivax Corp. learned that it would have to wait until at least 2004 to market its Paxene paclitaxel to treat Kaposi's sarcoma (KS) due to the Orphan Drug status held by Bristol-Myers Squibb's Taxol.

The Ivax collaboration was terminated soon after (see BioCentury, March 30, 1998). But NPRO now has found a way to take a second run at the market for paclitaxel, signing